Stuart H. Ellis

616 total citations
16 papers, 490 citations indexed

About

Stuart H. Ellis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Stuart H. Ellis has authored 16 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 4 papers in Physiology. Recurrent topics in Stuart H. Ellis's work include Statistical Methods in Clinical Trials (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Pain Mechanisms and Treatments (2 papers). Stuart H. Ellis is often cited by papers focused on Statistical Methods in Clinical Trials (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Pain Mechanisms and Treatments (2 papers). Stuart H. Ellis collaborates with scholars based in United Kingdom, Sweden and New Zealand. Stuart H. Ellis's co-authors include J McAinsh, Jay Cowen, Peter H. Sönksen, G. Sundkvist, J. M. Cruickshank, Matthew Ellis, Peter Aggett, Subhankar Chatterjee, G.A.J. Ayliffe and J.W.L. Davies and has published in prestigious journals such as Statistics in Medicine, European Journal of Cancer and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Stuart H. Ellis

16 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stuart H. Ellis United Kingdom	15	105	101	67	64	57	16	490
Chen‐Liang Tsai Taiwan	14	152 1.4×	371 3.7×	42 0.6×	36 0.6×	60 1.1×	43	748
Yu-Han Chang Taiwan	14	98 0.9×	133 1.3×	71 1.1×	95 1.5×	31 0.5×	27	599
Chunyan Su China	15	79 0.8×	76 0.8×	45 0.7×	6 0.1×	70 1.2×	52	725
Chou‐Chin Lan Taiwan	16	166 1.6×	413 4.1×	87 1.3×	15 0.2×	81 1.4×	90	828
Maria Grazia Scuderi Italy	15	32 0.3×	164 1.6×	44 0.7×	11 0.2×	21 0.4×	51	653
D Lonsdale United Kingdom	17	88 0.8×	101 1.0×	64 1.0×	6 0.1×	32 0.6×	49	666
Seon‐Sook Han South Korea	16	103 1.0×	257 2.5×	42 0.6×	11 0.2×	22 0.4×	46	668
Luqian Zhou China	17	139 1.3×	431 4.3×	22 0.3×	19 0.3×	27 0.5×	49	693
Eugene D. Davidson United States	15	142 1.4×	219 2.2×	94 1.4×	23 0.4×	45 0.8×	23	900
Bertram Fleshler United States	17	116 1.1×	136 1.3×	56 0.8×	99 1.5×	53 0.9×	42	1000

Countries citing papers authored by Stuart H. Ellis

Since Specialization

Citations

This map shows the geographic impact of Stuart H. Ellis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart H. Ellis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart H. Ellis more than expected).

Fields of papers citing papers by Stuart H. Ellis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart H. Ellis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart H. Ellis. The network helps show where Stuart H. Ellis may publish in the future.

Co-authorship network of co-authors of Stuart H. Ellis

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart H. Ellis. A scholar is included among the top collaborators of Stuart H. Ellis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart H. Ellis. Stuart H. Ellis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Schüler, Martin, Luis Paz‐Ares, Lecia V. Sequist, et al.. (2019). First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer. 133. 10–19. 23 indexed citations

Griebsch, Ingolf, Michael Palmer, Peter Fayers, & Stuart H. Ellis. (2014). Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib. BMJ Open. 4(10). e005762–e005762. 16 indexed citations

Khan, Fazal, Christian H. Ottensmeier, Sanjay Popat, et al.. (2014). Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. European Journal of Cancer. 50(10). 1717–1721. 10 indexed citations

Ellis, Stuart H., Kevin J. Carroll, & Kristine Pemberton. (2007). Analysis of duration of response in oncology trials. Contemporary Clinical Trials. 29(4). 456–465. 23 indexed citations

Krentz, Andrew J., L Honigsberger, Stuart H. Ellis, Matthew J. Hardman, & M. Nattrass. (1992). A 12‐Month Randomized Controlled Study of the Aldose Reductase Inhibitor Ponalrestat in Patients with Chronic Symptomatic Diabetic Neuropathy. Diabetic Medicine. 9(5). 463–468. 31 indexed citations

Sundkvist, G., et al.. (1992). Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. Journal of Diabetes and its Complications. 6(2). 123–130. 49 indexed citations

Ellis, Stuart H., et al.. (1991). A Study of Peripheral Diabetic Neuropathy. The Application of Age‐Related Reference Values. Diabetic Medicine. 8(S2). S94–9. 56 indexed citations

O’Neill, Paul, T. B. Stretton, R. D. Stark, & Stuart H. Ellis. (1986). The effect of indomethacin on breathlessness in patients with diffuse parenchymal disease of the lung. British Journal of Diseases of the Chest. 80(1). 72–79. 16 indexed citations

Baum, Marianna K., Diana Brinkley, Klim McPherson, et al.. (1985). Six‐year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. World Journal of Surgery. 9(5). 756–764. 16 indexed citations

10.

Whitehead, John, David R. Jones, & Stuart H. Ellis. (1983). The analysis of a sequential clinical trial for the comparison of two lung cancer treatments. Statistics in Medicine. 2(2). 183–190. 14 indexed citations

11.

Aggett, Peter, et al.. (1981). Percutaneous absorption of chlorhexidine in neonatal cord care.. Archives of Disease in Childhood. 56(11). 878–880. 43 indexed citations

12.

Ellis, Matthew, et al.. (1981). Cardioselectivity of atenolol in asthmatic patients. European Journal of Clinical Pharmacology. 21(3). 173–176. 53 indexed citations

13.

Baber, Nigel S., et al.. (1981). Bioavailability of sustained release propranolol formulations. Biopharmaceutics & Drug Disposition. 2(1). 39–48. 21 indexed citations

14.

Ellis, Stuart H., et al.. (1980). Bioavailability of atenolol formulations. Biopharmaceutics & Drug Disposition. 1(6). 323–332. 16 indexed citations

15.

Cowen, Jay, Stuart H. Ellis, & J McAinsh. (1979). Absorption of chlorhexidine from the intact skin of newborn infants.. Archives of Disease in Childhood. 54(5). 379–383. 65 indexed citations

16.

Davies, J.W.L., J.R. Babb, G.A.J. Ayliffe, & Stuart H. Ellis. (1977). The effect on the skin flora of bathing with antiseptic solutions. Journal of Antimicrobial Chemotherapy. 3(5). 473–481. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact